Metabolic drug interactions with new psychotropic agents

被引:104
|
作者
Spina, E [1 ]
Scordo, MG [1 ]
D'Arrigo, C [1 ]
机构
[1] Univ Messina, Pharmacol Sect, Dept Clin & Expt Med & Pharmacol, Policlin Univ, I-98125 Messina, Italy
关键词
antidepressants; antipsychotics; cytochrome P450 system; drug interactions; enzyme inhibition;
D O I
10.1046/j.1472-8206.2003.00193.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
New psychotropic drugs introduced in clinical practice in recent years include new antidepressants, such as selective serotonin reuptake inhibitors (SSRI) and 'third generation' antidepressants, and atypical antipsychotics, i.e. clozapine, risperidone, olanzapine, quetiapine, ziprasidone and amisulpride. These agents are extensively metabolized in the liver by cytochrome P450 (CYP) enzymes and are therefore susceptible to metabolically based drug interactions with other psychotropic medications or with compounds used for the treatment of concomitant somatic illnesses. New antidepressants differ in their potential for metabolic drug interactions. Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, while nefazodone is a potent inhibitor of CYP3A4. These antidepressants may be involved in clinically significant interactions when coadministered with substrates of these isoforms, especially those with a narrow therapeutic index. Other new antidepressants including sertraline, citalopram, venlafaxine, mirtazapine and reboxetine are weak in vitro inhibitors of the different CYP isoforms and appear to have less propensity for important metabolic interactions. The new atypical antipsychotics do not affect significantly the activity of CYP isoenzymes and are not expected to impair the elimination of other medications. Conversely, coadministration of inhibitors or inducers of the CYP isoenzymes involved in metabolism of the various antipsychotic compounds may alter their plasma concentrations, possibly leading to clinically significant effects. The potential for metabolically based drug interactions of any new psychotropic agent may be anticipated on the basis of knowledge about the CYP enzymes responsible for its metabolism and about its effect on the activity of these enzymes. This information is essential for rational prescribing and may guide selection of an appropriate compound which is less likely to interact with already taken medication(s).
引用
收藏
页码:517 / 538
页数:22
相关论文
共 50 条
  • [31] Psychotropic Drug–Drug Interactions Involving P-Glycoprotein
    Yumiko Akamine
    Norio Yasui-Furukori
    Ichiro Ieiri
    Tsukasa Uno
    CNS Drugs, 2012, 26 : 959 - 973
  • [32] Clinically significant interactions of psychotropic agents with antipsychotic drugs
    Meyer, MC
    Baldessarini, RJ
    Goff, DC
    Centorrino, F
    DRUG SAFETY, 1996, 15 (05) : 333 - 346
  • [33] Psychotropic drug interactions among drug-dependent people
    Schuelter-Trevisol, F.
    Zapelini do Nascimento, D.
    Moreno Marques, G.
    Trevisol, D. J.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30
  • [34] Inhibitory Metabolic Drug Interactions with Newer Psychotropic Drugs: Inclusion in Package Inserts and Influences of Concurrence in Drug Interaction Screening Software
    Boyce, Richard D.
    Collins, Carol
    Clayton, Marc
    Kloke, John
    Horn, John R.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (10) : 1287 - 1298
  • [35] Metabolic adverse drug reactions related to psychotropic drugs
    Gahr, Maximilian
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2025, 93 (03) : 95 - 103
  • [36] Psychotropic drug considerations in depressed patients with metabolic disturbances
    Vieweg, W. Victor R.
    Levy, James R.
    Fredrickson, Sonja K.
    Chipkin, Stuart R.
    Beatty-Brooks, Mary
    Fernandez, Antony
    Hasnain, Mehrul
    Pandurangi, Anand K.
    AMERICAN JOURNAL OF MEDICINE, 2008, 121 (08): : 647 - 655
  • [37] METABOLIC STUDIES OF TETRABENAZINE A PSYCHOTROPIC DRUG IN ANIMALS AND MAN
    SCHWARTZ, DE
    BRUDERER, H
    RIEDER, J
    BROSSI, A
    BIOCHEMICAL PHARMACOLOGY, 1966, 15 (05) : 645 - &
  • [38] Drug-drug interactions between psychotropic medications and oral contraceptives
    Schoretsanitis, Georgios
    Deligiannidis, Kristina M.
    Paulzen, Michael
    Spina, Edoardo
    de Leon, Jose
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (06) : 395 - 411
  • [39] NEW PSYCHOTROPIC-DRUG PHENAZEPAM
    ZAKUSOV, VV
    KHIMIKO-FARMATSEVTICHESKII ZHURNAL, 1979, 13 (10): : 108 - 112
  • [40] Consistency of psychotropic druge-drug interactions listed in drug monographs
    Liu, Xinyue
    Hatton, Randy C.
    Zhu, Yanmin
    Hincapie-Castillo, Juan M.
    Bussing, Regina
    Barnicoat, Marie
    Winterstein, Almut G.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2017, 57 (06) : 698 - +